tiprankstipranks
Trending News
More News >
PharmaNutra SpA (IT:PHN)
:PHN
Advertisement

PharmaNutra SpA (PHN) AI Stock Analysis

Compare
6 Followers

Top Page

IT

PharmaNutra SpA

(PHN)

Rating:66Neutral
Price Target:
€51.00
▲(10.99%Upside)
PharmaNutra SpA's stock score is primarily driven by its strong financial performance, with robust profitability and solid cash flow metrics. However, the stock's technical indicators reveal bearish trends, and its high P/E ratio suggests overvaluation concerns. The absence of notable earnings call insights or corporate events further concentrates the analysis on the core financial and technical data.
Positive Factors
Financial Performance
The company delivered a solid set of results, marked by double-digit top-line growth and continued its long-term investment cycle.
International Expansion
PharmaNutra reported a strong performance in foreign markets with a 24% year-over-year increase in net sales, indicating a robust international demand.
Product Leadership
Solid momentum was recorded across the main product families, with Sideral® confirming its market leadership in Italy.
Negative Factors
Investment Impact
Significant investments in new initiatives are expected to lead to a slight reduction in margins over the next two years.
Profitability Concerns
A margin drop is expected due to higher investment in new ventures, leading to a reduction in EBITDA and EPS estimates.
Revenue Expectations
The expected tangible results from PHN USA in H2 2025 are below expectations, affecting revenue projections.

PharmaNutra SpA (PHN) vs. iShares MSCI Italy ETF (EWI)

PharmaNutra SpA Business Overview & Revenue Model

Company DescriptionPharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
How the Company Makes MoneyPharmaNutra SpA generates revenue through the sale of its proprietary nutraceuticals and medical devices, primarily targeting iron deficiency and joint health. The company's key revenue streams include direct sales to pharmacies and healthcare providers, as well as distribution partnerships with pharmaceutical companies worldwide. Licensing agreements and international expansion play significant roles in its earnings, enabling PharmaNutra to leverage its patented technologies across diverse markets. Strategic alliances and a robust R&D pipeline further bolster its revenue potential by ensuring a steady flow of innovative products.

PharmaNutra SpA Financial Statement Overview

Summary
PharmaNutra SpA demonstrates strong financial performance with robust profitability metrics, including a net profit margin of 13.8% and an EBIT margin of 22.9%. The company's balance sheet is solid, with a moderate debt-to-equity ratio of 0.37, and cash flow is strong with a free cash flow growth rate of 27.3%. Minor areas for improvement include optimizing the gross profit margin and managing liabilities.
Income Statement
85
Very Positive
PharmaNutra SpA demonstrates strong financial performance with consistent revenue growth over the past years. The TTM data shows a gross profit margin of approximately 66.8% and a net profit margin of 13.8%, which are indicative of solid profitability. The EBIT margin is also robust at 22.9%, complemented by an EBITDA margin of 27.2%. These metrics suggest efficient cost management and operational effectiveness. However, the slight decline in gross profit from the previous period signals a potential area for improvement.
Balance Sheet
78
Positive
The company's balance sheet reflects a sound financial structure with a debt-to-equity ratio of 0.37, indicating moderate leverage. The equity ratio stands at 52.3%, showing a strong reliance on equity financing. Return on equity (ROE) is healthy at 25.5%, suggesting effective utilization of shareholder capital. However, the increase in total liabilities over time warrants cautious monitoring to ensure continued financial stability.
Cash Flow
82
Very Positive
PharmaNutra SpA's cash flow position is strong, with a significant free cash flow growth rate of 27.3% in the TTM period. The operating cash flow to net income ratio is 1.51, indicating robust cash generation from operations. The free cash flow to net income ratio is 1.26, highlighting good cash flow efficiency. Despite some fluctuations in capital expenditures, the company maintains a positive cash flow trajectory.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue116.79M101.03M83.39M68.58M58.48M
Gross Profit82.79M48.95M30.17M25.33M21.30M
EBITDA32.01M26.53M24.61M19.30M15.10M
Net Income16.61M12.83M15.05M13.77M14.07M
Balance Sheet
Total Assets117.47M112.44M100.16M71.36M51.71M
Cash, Cash Equivalents and Short-Term Investments29.10M25.12M26.86M33.94M20.80M
Total Debt24.27M28.02M17.73M6.35M1.66M
Total Liabilities55.27M58.04M49.21M26.27M13.98M
Stockholders Equity62.16M54.41M50.95M45.08M37.73M
Cash Flow
Free Cash Flow16.25M-1.16M-8.69M15.43M10.46M
Operating Cash Flow20.50M12.09M14.47M20.41M11.79M
Investing Cash Flow-2.21M-14.70M-23.71M-5.54M-598.00K
Financing Cash Flow-21.59M-516.00K1.89M-1.92M-4.73M

PharmaNutra SpA Technical Analysis

Technical Analysis Sentiment
Negative
Last Price45.95
Price Trends
50DMA
48.51
Negative
100DMA
49.81
Negative
200DMA
51.47
Negative
Market Momentum
MACD
-0.65
Negative
RSI
38.79
Neutral
STOCH
12.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHN, the sentiment is Negative. The current price of 45.95 is below the 20-day moving average (MA) of 46.42, below the 50-day MA of 48.51, and below the 200-day MA of 51.47, indicating a bearish trend. The MACD of -0.65 indicates Negative momentum. The RSI at 38.79 is Neutral, neither overbought nor oversold. The STOCH value of 12.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHN.

PharmaNutra SpA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
ITPHN
66
Neutral
€444.84M26.90
2.18%17.78%63.72%
52
Neutral
$7.46B-0.04-63.82%2.49%16.43%<0.01%
DE78Q
€655.04M19.1339.51%
€18.79M
€44.81M
€10.91M32.40
5.06%
ITSVS
€43.71M7.80
3.06%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IT:PHN
PharmaNutra SpA
45.90
-0.98
-2.09%
DE:78Q
Philogen SpA
21.50
1.10
5.39%
IT:COSMO
Farmacosmo S.P.A.
0.52
-0.22
-29.73%
IT:TALEA
Farmae SpA
5.28
-2.22
-29.60%
IT:ERFO
Laboratorio Farmaceutico Erfo SpA
1.26
0.18
16.67%
IT:SVS
Svas Biosana S.p.A.
8.06
0.06
0.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 09, 2025